---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-041986"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2022-04-04T23:59:59+00:00"
generated_at: "2026-06-26T09:40:51.850594+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eloxx Q4 net loss $12.1M; CF Foundation awards up to $15.9M; new Alport program

## Summary
- Net loss $12.1M in Q4 2021 ($0.14/sh); cash $42.3M; expects funding into Q2 2023.
- CF Foundation therapeutic award up to $15.9M for ELX-02 CF program; $7.0M upfront.
- Phase 2 CF expansion (ELX-02+ivacaftor) topline results expected by end of H1 2022.
- New Alport syndrome program for ELX-02; proof-of-concept trial in up to 8 patients expected H2 2022.
- ZKN-013 FAP mouse model: 50% reduction in polyp burden, 40% in polyp count; 50% survival benefit.

## SEC filing metadata
- accession: 0001104659-22-041986
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2022-04-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465922041986/0001104659-22-041986-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465922041986/tm2211418d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-041986
- JSON: https://secwatch.observer/filing/0001104659-22-041986.json
- Plain text: https://secwatch.observer/filing/0001104659-22-041986.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.